Cargando…

Management of aggressive fibromatosis

Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surroundin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhijun, Shi, Jian, Yang, Tao, Liu, Tongjun, Zhang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693298/
https://www.ncbi.nlm.nih.gov/pubmed/33262835
http://dx.doi.org/10.3892/ol.2020.12304
_version_ 1783614711916396544
author Zhang, Zhijun
Shi, Jian
Yang, Tao
Liu, Tongjun
Zhang, Kai
author_facet Zhang, Zhijun
Shi, Jian
Yang, Tao
Liu, Tongjun
Zhang, Kai
author_sort Zhang, Zhijun
collection PubMed
description Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surrounding organs, threatening life quality and expectancy. Although surgery, watch and wait, radiotherapy, chemotherapy, high intensity focused ultrasound, ablation techniques or several agents have all been frequently investigated for the treatment of this type of disease, none are deemed as standard therapy for high recurrence rates that have been supported by any data. The present review retrieved literature on treatment options for desmoids to summarize the latest treatment modalities and refine their efficacy, as well as their side effects, in order to provide a more comprehensive treatment reference for clinicians.
format Online
Article
Text
id pubmed-7693298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-76932982020-11-30 Management of aggressive fibromatosis Zhang, Zhijun Shi, Jian Yang, Tao Liu, Tongjun Zhang, Kai Oncol Lett Review Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surrounding organs, threatening life quality and expectancy. Although surgery, watch and wait, radiotherapy, chemotherapy, high intensity focused ultrasound, ablation techniques or several agents have all been frequently investigated for the treatment of this type of disease, none are deemed as standard therapy for high recurrence rates that have been supported by any data. The present review retrieved literature on treatment options for desmoids to summarize the latest treatment modalities and refine their efficacy, as well as their side effects, in order to provide a more comprehensive treatment reference for clinicians. D.A. Spandidos 2021-01 2020-11-17 /pmc/articles/PMC7693298/ /pubmed/33262835 http://dx.doi.org/10.3892/ol.2020.12304 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Zhang, Zhijun
Shi, Jian
Yang, Tao
Liu, Tongjun
Zhang, Kai
Management of aggressive fibromatosis
title Management of aggressive fibromatosis
title_full Management of aggressive fibromatosis
title_fullStr Management of aggressive fibromatosis
title_full_unstemmed Management of aggressive fibromatosis
title_short Management of aggressive fibromatosis
title_sort management of aggressive fibromatosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693298/
https://www.ncbi.nlm.nih.gov/pubmed/33262835
http://dx.doi.org/10.3892/ol.2020.12304
work_keys_str_mv AT zhangzhijun managementofaggressivefibromatosis
AT shijian managementofaggressivefibromatosis
AT yangtao managementofaggressivefibromatosis
AT liutongjun managementofaggressivefibromatosis
AT zhangkai managementofaggressivefibromatosis